Renal Cancer - Results from #1280

Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma. September 30, 2022

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China. September 30, 2022

On-Clamp vs. Off-Clamp Robot-Assisted Partial Nephrectomy for cT2 Renal Tumors: Retrospective Propensity-Score-Matched Multicenter Outcome Analysis. September 29, 2022

Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation. September 29, 2022

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy. September 27, 2022

The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. September 27, 2022

Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma As First-line Therapy: A Single Institution 13-year Experience. September 26, 2022

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. September 26, 2022

The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer. September 23, 2022

Recurrence pattern in localized RCC: results from a European multicenter database (RECUR). September 23, 2022

The Predictive Value of Three Variables in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-Based Combination Therapies in Randomized Clinical Trials: A Systematic Review and Meta-Analysis. September 22, 2022

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma. September 22, 2022

How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? September 22, 2022

SHMT2 regulates serine metabolism to promote the progression and immunosuppression of papillary renal cell carcinoma. September 21, 2022

A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. September 21, 2022

Predicting Oncologic Outcomes in Small Renal Tumors. September 20, 2022

The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. September 20, 2022

Machine learning-based prediction model for late recurrence after surgery in patients with renal cell carcinoma. September 19, 2022

Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. September 19, 2022

Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. September 16, 2022

Page 65 of 456